Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07368998 · ClinicalTrials.gov registry record · Phase 2
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 14
- Study locations
NCT07368998 is a Phase 2 study of Breast Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 14 study locations across 4 states.
The verdict
NCT07368998, a Phase 2 study of Breast Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Inavolisib
Study Locations (14)
Other
- Cliniques Universitaires St-Luc - Brussels
- UZ Leuven Gasthuisberg - Leuven
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona - Barcelona
- Hospital Universitario San Cecilio - Granada
- Hospital Universitario 12 De Octubre - Madrid
- Hospital Clinico Universitario de Valencia - Valencia
- Adana Baskent University Hospital - Adana
- Memorial Ankara Hastanesi - Ankara
- Medical Park Seyhan Hospital - Seyhan
- Princess Alexandra Hospital - Harlow
- Mount Vernon Cancer Centre - Northwood, Middlesex
California
- Los Angeles Cancer Network - Los Angeles
New Jersey
- Astera Cancer Care East Brunswick - East Brunswick
Istanbul
- Bagcilar Medipol Mega Universitesi Hastanesi - Bağcılar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2031-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07368998
The ClinicalTrials.gov registry entry for NCT07368998 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT07368998 reports 14 study locations spanning 4 distinct geographic areas - top geographies include Other, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07368998 about?
NCT07368998 is a clinical study titled "To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer". The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cy...
What is the current status of trial NCT07368998?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-02-18. Estimated completion is 2031-10-31.
What conditions does trial NCT07368998 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT07368998?
The interventions under investigation include: Fulvestrant (DRUG), Inavolisib (DRUG).
Who is sponsoring clinical trial NCT07368998?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07368998 being conducted?
This trial has 14 study locations across California, New Jersey, Istanbul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.